Nina Niu Sanford: FOLFIRINOX vs. Single Agent Gemcitabine in Locally Advanced Pancreas Cancer
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, reshared a post by Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, on X, adding:
“Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials – both w OS improvement!).
PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.”
Quoting Goutham Sunny‘s post:
“NEOPAN – Pancreatic Cancer Update.
In LAPC (locally advanced pancreatic cancer):
- Trial compared FOLFIRINOX vs Gemcitabine.
- 171 patients, PS ≤1, unresectable cases.
- Primary endpoint: PFS.
- Secondary endpoints: OS, QoL, safety
Results:
- Median PFS:
- FOLFIRINOX: 9.7 months
- Gemcitabine: 7.7 months
- HR = 0.7, P = .04
Median OS:
- FOLFIRINOX: 15.7 months.
- Gemcitabine: 15.4 months.
- HR = 1.02, P = .95
Better PFS with FOLFIRINOX
No OS benefit
Well tolerated.”
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, and Olivier Bouche.
You can read the full article on Journal of Clinical Oncology.
More posts featuring Nina Niu Sanford.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023